REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology. The presentations will take place at the 2020 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting being held in Philadelphia, Pa. from March 13 to 16, 2020.Oral Presentations:
Featured Poster Presentations:
Poster Presentations:
Following the presentations, the posters will be available on the Allakos website.About Allakos
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab (AK002) has been tested in five clinical studies. In these studies, antolimab (AK002) eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company’s website at www.allakos.comSource: Allakos Inc.
Bay Street News